Related Experiment Videos
New agents for the treatment of renal cell carcinoma
1Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, 22 South Greene Street, Baltimore, MD 21201, USA.
Abstract:
One-third of patients with renal cell carcinoma present with unresectable or metastatic disease. Immunotherapy, the current standard treatment, induces response in only 10-20% of patients. Chemotherapy with current agents is minimally effective. Other approaches including allogeneic stem cell transplant, vaccine and gene therapy and signal transduction inhibitors, offer promise in early Phase studies. This paper reviews the current treatment options and promising new agents in development.
Insights
Many advanced renal cell carcinoma patients lack effective treatments. This review covers current immunotherapies, chemotherapy, and promising new agents like stem cell transplants and gene therapy for better cancer care.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- One-third of renal cell carcinoma (RCC) patients present with advanced, unresectable, or metastatic disease.
- Current standard immunotherapy offers limited response rates (10-20%) in these patients.
- Chemotherapy demonstrates minimal efficacy in treating advanced RCC.
Purpose of the Study:
- To review current treatment modalities for advanced renal cell carcinoma.
- To highlight promising novel therapeutic agents currently in early-phase development.
Main Methods:
- Literature review of current and emerging treatments for renal cell carcinoma.
- Analysis of clinical trial data for novel therapeutic approaches.
Main Results:
- Immunotherapy and chemotherapy show limited effectiveness in advanced RCC.
- Early-phase studies indicate potential for allogeneic stem cell transplant, vaccine therapy, gene therapy, and signal transduction inhibitors.
Conclusions:
- There is a significant unmet need for effective treatments for advanced renal cell carcinoma.
- Novel therapeutic strategies beyond current standards show promise and warrant further investigation.